Differently from PON-1, the “in vivo” action of Lp-PLA2 is suggested to be beneficial only in some physiological and pathological settings [44, 45], whereas in others (e.g., atherosclerosis) seems to be detrimental [18, 44, 45]. The gene discussed is PON1; the disease is atherosclerosis.